Fig. 4From: Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trialAnnualised moderate/severe COPD exacerbation rates (ITT population). Bars represent adjusted exacerbation rate per patient per year and 95% CI. The N values are for the ITT population. COPD chronic obstructive pulmonary disease, ITT intention-to-treat, BDP beclometasone dipropionate, FF formoterol fumarate, G glycopyrronium, BUD budesonide, CI confidence intervalBack to article page